Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–70.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther. 1999;10(3):385–93.

Article  PubMed  CAS  Google Scholar 

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves Anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–e1910.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623(7985):157–66.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lang FF, Conrad C, Gomez-Manzano C, Yung WKA, Sawaya R, Weinberg JS, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419–27.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gallego Perez-Larraya J, Garcia-Moure M, Labiano S, Patino-Garcia A, Dobbs J, Gonzalez-Huarriz M, et al. Oncolytic DNX-2401 virus for pediatric diffuse intrinsic Pontine glioma. N Engl J Med. 2022;386(26):2471–81.

Article  PubMed  Google Scholar 

Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2023;29(6):1370–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, et al. Immune checkpoint therapy-current perspectives and future directions. Cell. 2023;186(8):1652–69.

Article  PubMed  CAS  Google Scholar 

Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, et al. Oncolytic HSV-1 G207 immunovirotherapy for pediatric High-Grade gliomas. N Engl J Med. 2021;384(17):1613–22.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160–77.

Article  PubMed  Google Scholar 

Ramelyte E, Tastanova A, Balázs Z, Ignatova D, Turko P, Menzel U, et al. Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. Cancer Cell. 2021;39(3):394–e4064.

Article  PubMed  CAS  Google Scholar 

Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651–9.

Article  PubMed  CAS  Google Scholar 

Challenor S, Tucker D. SARS-CoV-2-induced remission of hodgkin lymphoma. Br J Haematol. 2021;192(3):415.

Article  PubMed  CAS  Google Scholar 

Sollini M, Gelardi F, Carlo-Stella C, Chiti A. Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the flare phenomenon to the abscopal effect. Eur J Nucl Med Mol Imaging. 2021;48(8):2652–4.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kandeel EZ, Refaat L, Abdel-Fatah R, Samra M, Bayoumi A, Abdellateif MS, et al. Could COVID-19 induce remission of acute leukemia? Hematology. 2021;26(1):870–3.

Article  PubMed  CAS  Google Scholar 

Hoster HA, Zanes RP Jr., Von Haam E. Studies in hodgkin’s syndrome; the association of viral hepatitis and hodgkin’s disease; a preliminary report. Cancer Res. 1949;9(8):473–80.

PubMed  CAS  Google Scholar 

Southam CM, Moore AE. Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer. 1952;5(5):1025–34.

Article  PubMed  CAS  Google Scholar 

Georgiades J, Zielinski T, Cicholska A, Jordan E. Research on the oncolytic effect of APC viruses in cancer of the cervix uteri; preliminary report. Biul Inst Med Morsk Gdansk. 1959;10:49–57.

PubMed  CAS  Google Scholar 

Asada T. Treatment of human cancer with mumps virus. Cancer. 1974;34(6):1907–28.

Article  PubMed  CAS  Google Scholar 

Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991;252(5007):854–6.

Article  PubMed  CAS  Google Scholar 

Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274(5286):373–6.

Article  PubMed  CAS  Google Scholar 

Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000;7(10):867–74.

Article  PubMed  CAS  Google Scholar 

Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Ai Zheng. 2004;23(12):1666–70.

PubMed  Google Scholar 

Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8.

Article  PubMed  CAS  Google Scholar 

Todo T, Ito H, Ino Y, Ohtsu H, Ota Y, Shibahara J, et al. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nat Med. 2022;28(8):1630–9.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19(1):2–12.

Article  PubMed  CAS  Google Scholar 

Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, et al. Oncolytic adenovirus and Tumor-Targeting immune modulatory therapy improve autologous Cancer vaccination. Cancer Res. 2017;77(14):3894–907.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vinay DS, Ryan EP, Pawelec G, Talib WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol. 2015;35(Suppl):S185–98.

Article  PubMed  Google Scholar 

Saha D, Martuza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint Blockade. Cancer Cell. 2017;32(2):253–67. e5.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Paabo S, Severinsson L, Andersson M, Martens I, Nilsson T, Peterson PA. Adenovirus proteins and MHC expression. Adv Cancer Res. 1989;52:151–63.

Article  PubMed  CAS